Search clinical trials for: PF- 04965842

Total 1291 results

Pfizer

Completed

JAK1 Inhibitor With Medicated Topical Therapy in Adolescents With Atopic Dermatitis (JADE TEEN)

Atopic Dermatitis

Spain, United States, Taiwan, Germany, China, Hungary, Australia, Czechia, Japan, Latvia, Poland, United Kingdom, Mexico, Italy
Pfizer

Completed

AStudy to Evaluate the Bioavailability of PF 04965842 in Healthy Subjects

Healthy

Belgium
Biogen

Completed

Multiple Ascending Doses of PF-04958242 in Subjects With Stable Schizophrenia (MAD)

Schizophrenia

United States
Biogen

Completed

Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Single Doses Of PF-04958242 In Healthy Volunteers

Healthy

United States
Pfizer

Completed

Study to Investigate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over With Moderate to Severe Atopic Dermatitis With the Option of Rescue Treatment in Flaring Subjects

Skin Diseases | Immune System Diseases | Hypersensitivity | Hypersensitivity, Immediate | Genetic Diseases, Inborn | Skin Diseases, Genetic | Dermatitis | Eczema | Skin Diseases, Eczematous | Dermatitis, Atopic

United States, Spain, Taiwan, Germany, Canada, China, Poland, Belgium, Serbia, Brazil, Russian Federation, Israel, Latvia, Italy, Romania, Mexico, Argentina, Bulgaria, Chile, Netherlands, Slovakia
Biogen

Completed

Study Of The PF-04958242 Blood Concentrations Of A Capsule Formulation Of PF-04958242 Compared To A Solution Formulation

Healthy

United States
Biogen
Yale University

Completed

A Study To Assess Effects Of PF-04958242 On Bold Functional Magnetic Resonance Imaging During Working Memory Activation And Arterial Spin Labeling At Rest In Healthy Subjects

Healthy Volunteer

United States
Pfizer

Completed

Study Evaluating the Mechanism of Action of PF-04965842 Monotherapy for Moderate-to-severe Atopic Dermatitis (JADE MOA)

Atopic Dermatitis

United States, Canada
Pfizer

Completed

Study Evaluating Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis (JADE Mono-2)

Dermatitis, Atopic

China, United States, Australia, Poland, Hungary, Korea, Republic of, Germany, Bulgaria, Canada, Czechia, Japan, Latvia, United Kingdom
Biogen

Completed

First-in-Human Study of PF-04958242 in Healthy Volunteers

Healthy Volunteer

Singapore
Pfizer

Completed

Study to Evaluate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis (JADE Mono-1)

Dermatitis, Atopic

United States, Hungary, Canada, Germany, Australia, Czechia, Poland, United Kingdom
Biogen

Completed

A Study to Evaluate the Safety and Efficacy of BIIB104 in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS) (TALLY)

Cognitive Impairment Associated With Schizophrenia

Spain, United States, Germany, Japan, United Kingdom
Biogen

Completed

Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB104 in Healthy Japanese and Non-Japanese Participants

Healthy Volunteers

United States
Pfizer

Completed

Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy (JADE Compare)

Skin Diseases | Immune System Diseases | Hypersensitivity | Hypersensitivity, Immediate | Genetic Diseases, Inborn | Skin Diseases, Genetic | Dermatitis | Eczema | Skin Diseases, Eczematous | Dermatitis, Atopic

Spain, Taiwan, United States, Australia, Poland, Germany, Hungary, Bulgaria, Czechia, Japan, Korea, Republic of, Latvia, Canada, United Kingdom, Mexico, Chile, Slovakia, Italy
Biogen

Terminated

Study to Evaluate the Safety, Tolerability and Pharmacokinetics of PF-04958242 in Healthy Adult Volunteers

Healthy Volunteers

Singapore
Biogen

Completed

Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Repeated Doses of PF-04958242 in Healthy Volunteers

Schizophrenia

United States
Biogen

Completed

A Study Of The Effects Of PF-04958242 In Subjects With Age-Related Hearing Loss

Hearing Loss, Sensorineural

United States
Biogen

Completed

A Study To Examine The Safety, Tolerability And Pharmacokinetics Of PF-04958242 In Psychiatrically Stable Subjects With Schizophrenia

Schizophrenia

United States
Biogen

Terminated

A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)

Cognitive Impairment Associated With Schizophrenia (CIAS)

United States
Pfizer

Completed

A Hepatic Impairment Study for PF-04965842.

Hepatic Impairment

United States
Pfizer

Completed

A Renal Impairment Study for PF-04965842

Renal Impairment

United States, Belgium
Pfizer

Completed

Drug Drug Interaction Study Evaluating the Effect of Fluvoxamine or Fluconazole on PK and Safety of PF-04965842.

Dermatitis, Atopic

Belgium
Pfizer

Completed

Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis

Atopic Dermatitis

United States, Canada, Australia, Germany, Hungary
Pfizer

Terminated

Study to Evaluate PF-04965842 in Patients With Moderate to Severe Psoriasis

Plaque Psoriasis

United States, Canada
Pfizer

Completed

Absorption, Metabolism, Excretion and Absolute Bioavailability

Healthy

Netherlands
Pfizer

Completed

First-in-Human Study to Evaluate Safety and Tolerability of Single and Multiple Ascending Doses of Janus Kinase-1 Inhibitor PF-04965842 in Healthy Western and Japanese Subjects

Healthy

United States
Pfizer

Completed

Study of PF 04965842 Effect on MATE1/2K Activity in Healthy Participants

Healthy

Belgium
Pfizer

Completed

A Study to Assess Pharmacokinetics of PF-04965842 and Its Metabolites and Effect of Probenecid in Healthy Participants

Healthy

United States
Pfizer

Completed

Study of PF-04965842 Effect on Dabigatran Pharmacokinetics in Healthy Participants

Healthy

Belgium
Pfizer

Completed

A Study To Determine The Effect Of Single-dose PF-04965842 On QTc Interval In Healthy Volunteers Compared With Placebo and Moxifloxacin

Healthy Volunteers

Belgium
Skingenix, Inc.

Recruiting

Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns

Burns

United States
Pfizer

Completed

Study of PF-04965842 Effect on Rosuvastatin Pharmacokinetics in Healthy Participants

Healthy

Belgium
Pfizer

Completed

To Calculate the Pharmacokinetics (Concentration of Compound in and Rate of Excretion From the Blood) Following a Very Low Dose of Compound Which Will Not Have Any Pharmacological Activity

Healthy

United Kingdom
Pfizer

Completed

Study to Assess Pharmacokinetics, Safety and Tolerability of PF-04965842 in Chinese Healthy Participants

HEALTHY

China
Hospices Civils de Lyon

Recruiting

Evaluation of a Management Strategy for Second-degree Fibrinous Burns Integrating a Poly-absorbent Dressing (HYDRA-B)

Burns Degree Second

France
Pfizer

Completed

A Drug-Drug Interaction Study Between PF-06882961 and PF-06865571 in Healthy Adult Participants and Overweight Adults or Adults With Obesity Who Are Otherwise Healthy

Healthy Volunteer

United States
University of Florida

Completed

Potato Fiber and Gastrointestinal Function: Phase 3

Gastrointestinal Symptoms | Stool Frequency | Gastrointestinal Transit Time

United States
Pfizer

Completed

A DRUG-DRUG INTERACTION STUDY BETWEEN PF-06650833 AND PF-06651600 FOLLOWING MULTIPLE DOSES IN HEALTHY PARTICIPANTS

Healthy

United States
Pfizer

Completed

A Study To Examine Safety, Pharmacokinetics, And Pharmacodynamic Of Pf 06412562 In Subjects With Schizophrenia

Schizophrenia

United States
Pfizer

Completed

A Study to Understand the Effect of Tablet Formulation and Food on PF-06821497 in Healthy Adult Participants.

Healthy

United States
Pfizer

Completed

A First-in-human Study of Multiple Doses of Topically Administered PF-07295324 and PF-07259955

Healthy

United States
Pfizer

Completed

A Study To Assess The Safety Of PF-06342674 In Healthy Volunteers

Healthy

United States
Pfizer

Completed

Study To Evaluate Safety, Tolerability, And Pharmacokinetics Of PF-06473871 In Normal Healthy Adults

Healthy

Belgium
Pfizer

Completed

A Study To Observe Safety And Blood Concentrations Of PF-06412562 During And Following The Oral Administration Of Multiple Doses Of PF-06412562 In Healthy Adult Volunteers

Healthy

United States
Pfizer

Completed

A Study To Observe Safety And Concentrations Of PF-05297909 And Proteins In Both Blood And Cerebrospinal Fluid After A Single Dose Of PF-05297909 In Healthy Adults

Healthy

United States
Pfizer

Recruiting

A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis

Atopic Dermatitis

United States, Canada
Pfizer

Withdrawn

A Study To Examine The Safety And Efficacy Of PF-00610355 In Moderately Asthmatic Subjects (A7881006)

Respiratory Tract Diseases | Bronchial Diseases | Lung Diseases, Obstructive | Asthma, Bronchial
Pfizer

Completed

Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA) (MIRNA)

Nonalcoholic Fatty Liver Disease | Nonalcoholic Steatohepatitis With Liver Fibrosis

Hong Kong, United States, Taiwan, Puerto Rico, China, Canada, Korea, Republic of, Bulgaria, Japan, India, Poland, Slovakia
Pfizer

Completed

A Study in Healthy Adult Male Participants to Assess Absorption, Distribution, Metabolism and Excretion (ADME) of Radiolabeled PF-06865571.

Healthy Participants

United States
Pfizer

Completed

A Study To Assess The Safety Of PF-06342674 In Adults With Type 1 Diabetes

Diabetes Mellitus, Type 1

United States

3

Subscribe